Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine acetate monotherapy for newly diagnosed partial-onset seizures
2015-001243-36Phase 3Completed
- Sponsor
- BIAL
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eslicarbazepine acetate in epilepsy and Focal onset seizure (2 arms), sponsored by BIAL. Primary endpoint: Time to treatment failure. Started Aug 2015; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on 2015-001243-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001243-36.